Skip to main content
SpringerLink
Log in

Vancomycin-Induced Thrombocytopenia: A Narrative Review

  • Review Article
  • Published:
Drug Safety Aims and scope Submit manuscript

Abstract

Thrombocytopenia has been reported as an adverse reaction of numerous drugs. Vancomycin is often overlooked as a culprit but has been associated with several cases of thrombocytopenia that were not well described in the literature. A literature search was conducted to find reports of thrombocytopenia induced by vancomycin. Biomedical databases including ‘PubMed’, ‘Scopus’, and ‘Web of Science’ were searched using terms ‘vancomycin’, ‘platelet’, ‘pancytopenia’, ‘thrombocytopenia’, and ‘bleeding’. English language articles published before July 2015 were included. Thirty-nine papers including 29 case reports (30 cases), five observational studies, two clinical trials, two letters, and one case series remained for final analysis. The main route of administration was intravenous infusion. This adverse reaction seems to be duration dependent with the mean time to platelet nadir count of 8 days in reported cases. The interval may be significantly shorter in re-exposure to the drug. Platelet nadir counts ranged from 2000 to 100,000/mL in patients who experienced bleeding. Vancomycin-specific antibodies were detected in 13 of 17 patients who were tested in the case reports. Based on the Naranjo Adverse Drug Reaction Probability Scale, reaction was ‘definite’, ‘probable’, and ‘possible’ in 1, 15, and 14 patients, respectively. Among 30 cases, vancomycin was discontinued in 29 patients and platelets returned to normal counts within 5–6 days in 17 of them; in one patient, vancomycin was not discontinued, but platelet count recovered 11 days after the nadir time. Transfusion might be recommended if severe thrombocytopenia and bleeding occurs. Intravenous immunoglobulins, corticosteroids, rituximab, and plasma exchange should be reserved for patients with resistant thrombocytopenia and severe bleeding as mentioned in a number of reports.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Aster RH, Curtis BR, McFarland JG, Bougie DW. Drug-induced immune thrombocytopenia: pathogenesis, diagnosis, and management. J Thromb Haemost. 2009;7(6):911–8. doi:10.1111/j.1538-7836.2009.03360.x.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Rondina MT, Walker A, Pendleton RC. Drug-induced thrombocytopenia for the hospitalist physician with a focus on heparin-induced thrombocytopenia. Hosp Pract (1995). 2010;38(2):19–28.

    PubMed Central  Google Scholar 

  3. van den Bemt PM, Meyboom RH, Egberts AC. Drug-induced immune thrombocytopenia. Drug Saf. 2004;27(15):1243–52. doi:10.2165/00002018-200427150-00007.

    Article  PubMed  Google Scholar 

  4. Aster RH, Bougie DW. Drug-induced immune thrombocytopenia. N Engl J Med. 2007;357(6):580–7. doi:10.1056/NEJMra066469.

    Article  PubMed  Google Scholar 

  5. Kenney B, Stack G. Drug-induced thrombocytopenia. Arch Pathol Lab Med. 2009;133(2):309–14. doi:10.1043/1543-2165-133.2.309.

    PubMed  Google Scholar 

  6. Arnold DM, Kukaswadia S, Nazi I, et al. A systematic evaluation of laboratory testing for drug-induced immune thrombocytopenia. J Thromb Haemost. 2013;11(1):169–76. doi:10.1111/jth.12052.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Priziola JL, Smythe MA, Dager WE. Drug-induced thrombocytopenia in critically ill patients. Crit Care Med. 2010;38(6 Suppl.):S145–54. doi:10.1097/CCM.0b013e3181de0b88.

    Article  PubMed  Google Scholar 

  8. Patnode NM, Gandhi PJ. Drug-induced thrombocytopenia in the coronary care unit. J Thromb Thrombolysis. 2000;10(2):155–67.

    Article  CAS  PubMed  Google Scholar 

  9. Von Drygalski A, Curtis BR, Bougie DW, et al. Vancomycin-induced immune thrombocytopenia. N Engl J Med. 2007;356(9):904–10. doi:10.1056/NEJMoa065066.

    Article  Google Scholar 

  10. Levine DP. Vancomycin: understanding its past and preserving its future. South Med J. 2008;101(3):284–91. doi:10.1097/SMJ.0b013e3181647037.

    Article  PubMed  Google Scholar 

  11. Black E, Lau TT, Ensom MH. Vancomycin-induced neutropenia: is it dose- or duration-related? Ann Pharmacother. 2011;45(5):629–38. doi:10.1345/aph.1P583.

    Article  CAS  PubMed  Google Scholar 

  12. Ganly P, Downing J, Stiven P, et al. Clinical and serological diagnoses of a patient with vancomycin-induced thrombocytopenia. Transfus Med. 2011;21(2):137–9.

    Article  CAS  PubMed  Google Scholar 

  13. Anand A, Chauhan HK. Piperacillin and vancomycin induced severe thrombocytopenia in a hospitalized patient. Platelets. 2011;22(4):294–301. doi:10.3109/09537104.2010.549973.

    Article  CAS  PubMed  Google Scholar 

  14. Apiwattanakul N, Wanitkun S, Chongtrakool P, Sirinavin S. A patient with penicillin-resistant viridans group streptococcal endocarditis and unusual reactions to vancomycin. Southeast Asian J Trop Med Public Health. 2008;39(6):1088–91.

    PubMed  Google Scholar 

  15. Bay A, Oner AF, Dogan M, Çaksen H. A child with vancomycin-induced thrombocytopenia. J Emerg Med. 2006;30(1):99–100.

    Article  PubMed  Google Scholar 

  16. Candemir B, Aribuca A, Koca C, et al. An unusual case of vancomycin-related systemic reaction accompanied with severe thrombocytopenia mimicking pacemaker-related infective endocarditis: a case report and review of literature. J Interv Card Electrophysiol. 2013;38(2):143–5. doi:10.1007/s10840-012-9738-6.

    Article  PubMed  Google Scholar 

  17. Carmichael A, Al-Zahawi M. Drug points: pancytopenia associated with vancomycin. BMJ. 1986;293(6554):1103.

    Article  PubMed Central  Google Scholar 

  18. Christie DJ, van Buren N, Lennon SS, Putnam JL. Vancomycin-dependent antibodies associated with thrombocytopenia and refractoriness to platelet transfusion in patients with leukemia. Blood. 1990;75(2):518–23.

    CAS  PubMed  Google Scholar 

  19. Govindarajan R, Baxter D, Wilson C, Zent C. Vancomycin-induced thrombocytopenia. Am J Hematol. 1999;62(2):122–3.

    Article  CAS  PubMed  Google Scholar 

  20. Kenney B, Tormey CA. Acute vancomycin-dependent immune thrombocytopenia as an anamnestic response. Platelets. 2008;19(5):379–83. doi:10.1080/09537100802082280.

    Article  CAS  PubMed  Google Scholar 

  21. Kuruppu JC, Le TP, Tuazon CU. Vancomycin-associated thrombocytopenia: case report and review of the literature. Am J Hematol. 1999;60(3):249–50.

    Article  CAS  PubMed  Google Scholar 

  22. Lee JH, Kim DS, Lee HS, et al. A case of vancomycin-induced thrombocytopenia. Korean J Hematol. 2009;44(4):294–7.

    Article  Google Scholar 

  23. Marraffa J, Guharoy R, Duggan D, et al. Vancomycin-induced thrombocytopenia: a case proven with rechallenge. Pharmacotherapy. 2003;23(9):1195–8.

    Article  PubMed  Google Scholar 

  24. Mizon P, Kiefel V, Mannessier L, et al. Thrombocytopenia induced by vancomycin-dependent platelet antibody. Vox Sang. 1997;73(1):49–51.

    Article  CAS  PubMed  Google Scholar 

  25. O’Donnell E, Shepherd C, Neff A. Immune thrombocytopenia from vancomycin in orthopedic cement. Am J Hematol. 2007;82(12):1122.

    Article  PubMed  Google Scholar 

  26. Ortín BP, Solis MA, Ramos VB, et al. Thrombocytopenia in a patient on peritoneal dialysis. Nefrologia. 2008;28(4):453–5.

    Google Scholar 

  27. Pauldine R, Pustavoitau A. Case report: vancomycin-induced thrombocytopenia in a burn patient. Eplasty. 2008;8:e39.

    PubMed  PubMed Central  Google Scholar 

  28. Peel RK, Sykes A, Ashmore S, et al. A case of immune thrombocytopenic purpura from intraperitoneal vancomycin use. Perit Dial Int. 2003;23(5):506–8.

    PubMed  Google Scholar 

  29. Rocha JL, Kondo W, Baptista MI, et al. Uncommon vancomycin-induced side effects. Braz J Infect Dis. 2002;6(4):196–200.

    Article  PubMed  Google Scholar 

  30. Ruggero MA, Abdelghany O, Topal JE. Vancomycin-induced thrombocytopenia without isolation of a drug-dependent antibody. Pharmacotherapy. 2012;32(11):e321–5. doi:10.1002/phar.1132.

    Article  PubMed  Google Scholar 

  31. Shah RA, Musthaq A, Khardori N. Vancomycin-induced thrombocytopenia in a 60-year-old man: a case report. J Med Case Rep. 2009;3:7290. doi:10.4076/1752-1947-3-7290.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Shahar A, Berner Y, Levi S. Fever, rash, and pancytopenia following vancomycin rechallenge in the presence of ceftazidime. Ann Pharmacother. 2000;34(2):263–4.

    Article  CAS  PubMed  Google Scholar 

  33. Winteroll S, Kerowgan M, Vahl C-F, Leo A. Vancomycin-mediated drug-induced immune thrombocytopenia. Transfus Med Hemother. 2004;32(1):20–3.

    Article  Google Scholar 

  34. Zenon GJ, Cadle RM, Hamill RJ. Vancomycin-induced thrombocytopenia. Arch Intern Med. 1991;151(5):995–6.

    Article  CAS  PubMed  Google Scholar 

  35. Dilli D, Oguz SS, Dilmen U. A newborn with vancomycin-induced thrombocytopenia. Pharmacology. 2008;82(4):285–6. doi:10.1159/000163099.

    Article  CAS  PubMed  Google Scholar 

  36. Walker RW, Heaton A. Thrombocytopenia due to vancomycin. Lancet. 1985;1(8434):932.

    Article  CAS  PubMed  Google Scholar 

  37. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239–45. doi:10.1038/clpt.1981.154.

    Article  CAS  PubMed  Google Scholar 

  38. George JN, Aster RH. Drug-induced thrombocytopenia: pathogenesis, evaluation, and management. Hematol Am Soc Hematol Educ Program. 2009:153–8. doi:10.1182/asheducation-2009.1.153.

  39. George J, Raskob G, Shah S, et al. Drug-induced thrombocytopenia: a systematic review of published case reports. Ann Intern Med. 1998;129(11):886–90.

    Article  CAS  PubMed  Google Scholar 

  40. Bonfiglio MF, Traeger SM, Kier KL, et al. Thrombocytopenia in intensive care patients: a comprehensive analysis of risk factors in 314 patients. Ann Pharmacother. 1995;29(9):835–42.

    CAS  PubMed  Google Scholar 

  41. Howard CE, Adams LA, Admire JL, et al. Vancomycin-induced thrombocytopenia: a challenge and rechallenge. Ann Pharmacother. 1997;31(3):315–8.

    CAS  PubMed  Google Scholar 

  42. Linder N, Edwards R, MeClead R, et al. Safety of vancomycin with or without gentamicin in neonates. Neonatal Netw. 1993;12(8):27–30.

    CAS  PubMed  Google Scholar 

  43. Wood MJ. Comparative safety of teicoplanin and vancomycin. J Chemother. 2000;12(Suppl. 5):21–5.

    Article  CAS  Google Scholar 

  44. Ahmed Y, Sartin C, Umer I, et al. Vancomycin-induced severe asymptomatic immune thrombocytopenia; a rare cause. Southwest Respir Crit Care Chronicles. 2015;3(9):42–5.

    Google Scholar 

  45. Arnold DM, Nazi I, Warkentin TE, et al. Approach to the diagnosis and management of drug-induced immune thrombocytopenia. Transfus Med Rev. 2013;27(3):137–45. doi:10.1016/j.tmrv.2013.05.005.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Lobo N, Ejiofor K, Thurairaja R, Khan MS. Life-threatening haematuria caused by vancomycin-induced thrombocytopenia. BMJ Case Rep. 2015;2015. doi:10.1136/bcr-2014-208192.

  47. Rowland SP, Rankin I, Sheth H. Vancomycin-induced thrombocytopaenia in a patient with severe pancreatitis. BMJ Case Rep. 2013;2013. doi:10.1136/bcr-2013-200830.

  48. Wetzel DR, Njathi CW, Telesz BJ, et al. Thrombocytopenia of unusual etiology in the intensive care unit. J Med Cases. 2013;4(12):792.

    Google Scholar 

  49. Marinho DS, Huf G, Ferreira BL, et al. The study of vancomycin use and its adverse reactions associated to patients of a Brazilian university hospital. BMC Res Notes. 2011;4:236. doi:10.1186/1756-0500-4-236.

    Article  PubMed  PubMed Central  Google Scholar 

  50. Moenster RP, Linneman TW, Finnegan PM, McDonald JR. Daptomycin compared to vancomycin for the treatment of osteomyelitis: a single-center, retrospective cohort study. Clin Ther. 2012;34(7):1521–7. doi:10.1016/j.clinthera.2012.06.013.

    Article  CAS  PubMed  Google Scholar 

  51. Domen RE. Vancomycin-induced cytopenias. Arch Intern Med. 1992;152(2):413–4.

    Article  CAS  PubMed  Google Scholar 

  52. Bougie DW, Wilker PR, Aster RH. Patients with quinine-induced immune thrombocytopenia have both “drug-dependent” and “drug-specific” antibodies. Blood. 2006;108(3):922–7. doi:10.1182/blood-2006-01-009803.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Patel N, VanDeWall H, Tristani L, et al. A comparative evaluation of adverse platelet outcomes among Veterans’ Affairs patients receiving linezolid or vancomycin. J Antimicrob Chemother. 2012;67(3):727–35. doi:10.1093/jac/dkr522.

    Article  CAS  PubMed  Google Scholar 

  54. Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2009;66(1):82–98. doi:10.2146/ajhp080434.

    Article  CAS  PubMed  Google Scholar 

  55. Vandecasteele SJ, De Vriese AS. Recent changes in vancomycin use in renal failure. Kidney Int. 2010;77(9):760–4. doi:10.1038/ki.2010.35.

    Article  CAS  PubMed  Google Scholar 

  56. Wilson AP. Comparative safety of teicoplanin and vancomycin. Int J Antimicrob Agents. 1998;10(2):143–52.

    Article  CAS  PubMed  Google Scholar 

  57. Jaksic B, Martinelli G, Perez-Oteyza J, et al. Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer. Clin Infect Dis. 2006;42(5):597–607. doi:10.1086/500139.

    Article  CAS  PubMed  Google Scholar 

  58. Kohno S, Yamaguchi K, Aikawa N, et al. Linezolid versus vancomycin for the treatment of infections caused by methicillin-resistant Staphylococcus aureus in Japan. J Antimicrob Chemother. 2007;60(6):1361–9. doi:10.1093/jac/dkm369.

    Article  CAS  PubMed  Google Scholar 

  59. Young LS. Hematologic effects of linezolid versus vancomycin. Clin Infect Dis. 2004;38(8):1065–6. doi:10.1086/382364.

    Article  PubMed  Google Scholar 

  60. Hsiao SH, Chou CH, Lin WL, et al. High risk of cross-reactivity between vancomycin and sequential teicoplanin therapy. J Clin Pharm Ther. 2012;37(3):296–300. doi:10.1111/j.1365-2710.2011.01291.x.

    Article  CAS  PubMed  Google Scholar 

  61. Rao N, Ziran BH, Wagener MM, et al. Similar hematologic effects of long-term linezolid and vancomycin therapy in a prospective observational study of patients with orthopedic infections. Clin Infect Dis. 2004;38(8):1058–64. doi:10.1086/382356.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Faculty of Pharmacy, Tehran University of Medical Sciences, Pour Sina St, District 6, Tehran, Iran

    Mehdi Mohammadi, Zahra Jahangard-Rafsanjani & Molouk Hadjibabaei

  2. Research Center for Rational Use of Drugs, Tehran University of Medical Sciences, 4th Floor, No. 92, Karimkhan Zand Avenue, Hafte Tir Square, Tehran, Iran

    Amir Sarayani, Molouk Hadjibabaei & Maryam Taghizadeh-Ghehi

Authors
  1. Mehdi Mohammadi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Zahra Jahangard-Rafsanjani
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Amir Sarayani
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Molouk Hadjibabaei
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Maryam Taghizadeh-Ghehi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Maryam Taghizadeh-Ghehi.

Ethics declarations

Funding

No sources of funding were used to assist in the preparation of this article.

Conflict of interest

Mehdi Mohammadi, Zahra Jahangard-Rafsanjani, Amir Sarayani, Molouk Hadjibabaei, and Maryam Taghizadeh-Ghehi have no conflicts of interest that are directly relevant to the content of this article.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mohammadi, M., Jahangard-Rafsanjani, Z., Sarayani, A. et al. Vancomycin-Induced Thrombocytopenia: A Narrative Review. Drug Saf 40, 49–59 (2017). https://doi.org/10.1007/s40264-016-0469-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40264-016-0469-y

Keywords

Search

Navigation